Bisphosphonate induced hypocalcaemia - Report of six cases and review of the literature

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Kreutle, Veronika ^a   Blum, Claudine ^b   Meier, Christian ^b   Past, Miriam ^a   Mueller, Beat ^a   Schuetz, Philipp ^a   Borm, Katrin ^a  

^a Department of Endocrinology Diabetology and Metabolism Medical University Hospital Aarau   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bisphosphonates; Hypocalcaemia

Indexed keywords

BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CALCITRIOL; CALCIUM CARBONATE; CAPECITABINE; COLECALCIFEROL; EPIRUBICIN; GLUCONATE CALCIUM; LEUPRORELIN; MAGNESIUM SULFATE; OXALIPLATIN; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCIUM; IMIDAZOLE DERIVATIVE; VITAMIN;

ADULT; AGED; ANTIANDROGEN THERAPY; BABINSKI REFLEX; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER THERAPY; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOCALCEMIA; MALE; MIDDLE AGED; PROSTATE ADENOCARCINOMA; REVIEW; STOMACH CANCER; TENDON REFLEX; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CASE REPORT; CHEMICALLY INDUCED;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; MALE; MIDDLE AGED; VITAMINS;

EID: 84903832629     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.13979     Document Type: Review

References (35)

1. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly. 2012;142:w13624.
2. Meier C, Kraenzlin ME. Curriculum Osteoporose: Therapie-Update 2013, Teil 2. Medikamente heute und morgen. Swiss Med Forum. 2013;13(42):835-40.
3. Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, et al. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast. 2012;21(4):544-9.
4. Ho JW, Sundar S. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clin Genitourin Cancer. 2012;10(1):50-3.
5. Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013;29(9):1067-73.
6. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.
7. Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, et al. Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone. 2013;55(2):305-8.
8. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J. 2008;38(8):635-7.
9. Zuradelli M, Masci G, Biancofiore G, Gullo G, Scorsetti M, Navarria P, et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist. 2009;14(5):548-56.
10. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate- induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12(1):48-53.
11. Joshi A, Price E, Collins D, Williamson L. Comment on: "Hypovitaminosis D among rheumatology outpatients in clinical practice". Rheumatology (Oxford). 2009;48(2):203-4; author reply 4.
12. Sims EC, Rogers PB, Besser GM, Plowman PN. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Clin Oncol (R Coll Radiol). 1998;10(6):407-9. (Pubitemid 29015251)
13. Tsukasa K, Fujimoto C, Ariyama H, Esaki T, Murakawa M, Syoji T, et al. A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy. Gan To Kagaku Ryoho. 2009;36(3):489-92.
14. Tsourdi E, Rachner TD, Gruber M, Hamann C, Ziemssen T, Hofbauer LC. Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab. 2011;96(7):1955-9.
15. Ho JW. Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia. Med Hypotheses. 2012;78(3):377-9.
16. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20(2):239-44.
17. Mouyis M, Ostor AJ, Crisp AJ, Ginawi A, Halsall DJ, Shenker N, et al. Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology (Oxford). 2008;47(9):1348-51.
18. Segal E, Felder S, Haim N, Yoffe-Sheinman H, Peer A, Wollner M, et al. Vitamin D deficiency in oncology patients - an ignored condition: impact on hypocalcemia and quality of life. Isr Med Assoc J. 2012;14(10):607-12.
19. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420-32.
20. Guessous I, Dudler V, Glatz N, Theler JM, Zoller O, Paccaud F, et al. Vitamin D levels and associated factors: a population-based study in Switzerland. Swiss Med Wkly. 2012;142:0.
21. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013;24(5):1141-62.
22. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897-907. (Pubitemid 43785797)
23. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57. (Pubitemid 350191297)
24. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80-100. (Pubitemid 29122075)
25. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68.
26. Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, et al. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. J Bone Miner Metab. 2010;28(6):706-12.
27. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004;328(7435):335-6. (Pubitemid 38197856)
28. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22. (Pubitemid 46698462)
29. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298-302. (Pubitemid 351839635)
30. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221-7.
31. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464-72. (Pubitemid 46999218)
32. Berenson JR, Stopeck AT. Risks of therapy with bone modifying agents in patients with advanced malignancy www.uptodate.com: uptodate.
33. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 2011;71(6):791-814.
34. Fallah-Rad N, Morton AR. Managing hypercalcaemia and hypocalcaemia in cancer patients. Curr Opin Support Palliat Care. 2013;7(3):265-71.
35. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657-66. (Pubitemid 47285316)